| Market cap | $343.00B |
|---|---|
| Enterprise value | $786.96B |
| Revenue | $35.932B |
|---|---|
| EBITDA | $12.912B |
| Income | $6.138B |
| Revenue Q/Q | 25.98% |
| Revenue Y/Y | 29.76% |
| P/E | 130.71 |
|---|---|
| Forward P/E | 68.56 |
| EV/Sales | 21.90 |
| EV/EBITDA | 60.95 |
| EV/EBIT | 104.08 |
| PEG | 2.18 |
| Price/Sales | 9.55 |
| P/FCF | N/A |
| Price/Book | 31.84 |
| Book/Share | 28.00 |
| Cash/Share | 7.61 |
| FCF yield | -0.03% |
| Volume | 2.414M / 2.160M |
|---|---|
| Relative vol. | 1.12 × |
| EPS | 6.82 |
|---|---|
| EPS Q/Q | 15.79% |
| Est. EPS Q/Q | -22.09% |
| Profit margin | 15.36% |
|---|---|
| Oper. margin | 21.04% |
| Gross margin | 79.25% |
| EBIT margin | 21.04% |
| EBITDA margin | 35.93% |
| Ret. on assets | 10.20% |
|---|---|
| Ret. on equity | 53.53% |
| ROIC | 11.57% |
| ROCE | 16.67% |
| Debt/Equity | 4.93 |
|---|---|
| Net debt/EBITDA | 6.16 |
| Current ratio | 1.35 |
| Quick ratio | 1.03 |
| Volatility | 1.95% |
|---|---|
| Beta | 0.58 |
| RSI | 80.59 |
|---|
| Insider ownership | 0.21% |
|---|---|
| Inst. ownership | 84.30% |
| Shares outst. | 950.405M |
|---|---|
| Shares float | 0.000 0.00% |
| Short % of float | 0.84% |
| Short ratio | 1.96 |
| Dividend | $4.86 |
|---|---|
| Dividend yield | 0.55% |
| Payout ratio | 71.26% |
| Payment date | N/A |
| Ex-dividend date | N/A |
| Earnings date | 8 Aug 2024 |
Monday, 17 June 2024
|
|
| New Weight-Loss Drugs and Devices Are Coming This Week | |
Thursday, 13 June 2024
|
|
| Billionaire Israel Englander is Buying This Weight Loss Stock in 2024 | |
Monday, 10 June 2024
|
|
| FDA panel votes unanimously for Eli Lilly's Alzheimer's treatment | |
| Alzheimer's drug that can slow disease gets backing from FDA advisers | |
Friday, 7 June 2024
|
|
| Is Eli Lilly and Company A Good “Quality Stock” to Buy Now? | |
Thursday, 6 June 2024
|
|
| How Alphabet Could Become the Next $3 Trillion Stock | |
Monday, 3 June 2024
|
|
| Eli Lilly Beefs Up Neuro Pipeline With Addition Of Preclinical ALS, Dementia Prospect | |
Friday, 31 May 2024
|
|
| ZTS, SYK, LLY: Which Healthcare Stock Is the Best Buy? | |
Saturday, 25 May 2024
|
|
| The Biggest Publicly Traded Biotech Company | |
Friday, 24 May 2024
|
|
| Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, Mounjaro | |
Wednesday, 22 May 2024
|
|
| Is Eli Lilly and Company the Largest Publicly Traded Healthcare Company? | |
Tuesday, 21 May 2024
|
|
| Dow Jones Futures: Nasdaq Hits High, Eli Lilly Breaks Out, But Here Comes Nvidia | |
| IBD Stock Of The Day Eli Lilly Breaks Out On Its Way To A Record High | |
| Eli Lilly's diabetes drug tirzepatide gets approval in China | |
Thursday, 16 May 2024
|
|
| UPDATE 1-Lilly's weekly insulin succeeds in late-stage studies | |
Wednesday, 15 May 2024
|
|
| Dow Jones Futures: Dow, S&P 500, Nasdaq Hit Highs, Nvidia Leads 12 New Buys; What To Do Now | |
| Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound | |
| UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down | |
Monday, 13 May 2024
|
|
| Wegovy weight loss sustained for four years in trial, Novo Nordisk says | |
| Pfizer Follows Eli Lilly's Footsteps To Sell Medicines Directly To Patients | |
Tuesday, 7 May 2024
|
|
| 13 Best Stocks That Will Always Grow | |
| Kevin O’Leary’s Stock Portfolio: 10 Stock Picks for 2024 | |
| UPDATE 1-US FDA panel to discuss Eli Lilly Alzheimer's drug on June 10 | |
| Mutual Funds Can't Get Enough Amazon, Broadcom | |
Friday, 3 May 2024
|
|
| Amazon Stock Is on a Roll. Here’s Why It’s on This Firm’s ‘Best Ideas List.’ | |
Thursday, 2 May 2024
|
|
| Amgen Soars After CEO Gives Update on Experimental Obesity Drug | |
| Novo Nordisk’s Wegovy Sales More Than Doubled. Why the Stock Is Falling. | |
| Obesity drugmaker Novo Nordisk raises outlook, Q1 profit beats forecast | |
Wednesday, 1 May 2024
|
|
| This Options-Backed Strategy Can Help You Dodge the Stock Market’s Hazards | |
| Decoding Eli Lilly and Co : A Strategic SWOT Insight | |
Tuesday, 30 April 2024
|
|
| US Equity Markets Close Down Tuesday After Higher Wage Data | |
| Stocks Keep Sinking, With Dow Losing 400 Points; IBD 50 Stock Hubbell Plunges | |
| IBD Stock Of The Day Eli Lilly Surges After Weight-Loss Drug Obliterates Sales Views | |
| Eli Lilly's Weight-Loss Drug Still Going Strong, Boosts Annual Forecast | |
| Insider |
Trans.
Transaction
|
Total value |
|---|---|---|
| Endowment Inc Lilly | Sale 17 Jun 2024 | $172,732,960 |
| Endowment Inc Lilly | Sale 14 Jun 2024 | $13,256,464 |
| Endowment Inc Lilly | Sale 10 Jun 2024 | $64,997,498 |
| Endowment Inc Lilly | Sale 7 Jun 2024 | $118,885,932 |
| Endowment Inc Lilly | Sale 6 Jun 2024 | $150,486,715 |
| Endowment Inc Lilly | Sale 5 Jun 2024 | $17,046,711 |
| Endowment Inc Lilly | Sale 3 Jun 2024 | $159,974,677 |
| Donald A Zakrowski SVP, Finance, and CAO | Sale 3 Jun 2024 | $614,603 |
| Johna Norton EVP and Global Quality | Sale 3 Jun 2024 | $5,781,545 |
| Diogo Rau EVP and CIDO | Option 1 Jun 2024 | $5,168,142 |
| Endowment Inc Lilly | Sale 31 May 2024 | $18,255,775 |
Powered by
Robintrack.
Price target
Current $837.29
Average $168.80
Low $143
High $200
Dividends
| Ex-dividend date | N/A | Frequency | Quarterly | Annual dividend | +15.31% |
|---|---|---|---|---|---|
| Next dividend | N/A | Dividend yield | 0.55% | Growth period | 51 years |
| Last dividend date | Yield 3 years | 0.80% | Growth 3 years | +15.15% | |
| Last dividend | Yield 5 years | 1.08% | Growth 5 years | +14.96% |
| Insider | Age | Since | Compensation |
|---|---|---|---|
| David Ricks (52) Chairman of the Board, President, and Chief Executive Officer since 2017 | 52 | 2017 | $21,283,200 |
| Joshua Smiley (50) Chief Financial Officer and Senior Vice President since 2018 | 50 | 2018 | $7,348,400 |
| Daniel Skovronsky (47) Senior Vice President, Chief Scientific Officer, President, and Lilly Research Laboratories since 2018 | 47 | 2018 | $6,662,970 |
| David A. Ricks (53) Chairman, CEO, and Pres | 53 | $4,237,205 | |
| Anat Hakim J.D. (52) Sr. VP, Gen. Counsel, and Sec. | 52 | $1,720,656 | |
| Jackson Tai (70) Independent Director since 2013 | 70 | 2013 | $357,000 |
| Juan Luciano (58) Lead Independent Director since 2019 | 58 | 2019 | $326,333 |
| J. Erik Fyrwald (60) Independent Director since 2005 | 60 | 2005 | $325,000 |
| Karen Walker (58) Independent Director since 2018 | 58 | 2018 | $319,000 |
| William Kaelin (62) Independent Director since 2012 | 62 | 2012 | $312,000 |
| Michael Eskew (70) Independent Director since 2008 | 70 | 2008 | $311,000 |
| Jamere Jackson (51) Independent Director since 2016 | 51 | 2016 | $306,000 |
| Katherine Baicker (48) Independent Director since 2011 | 48 | 2011 | $306,000 |
| Raul Alvarez (64) Independent Director since 2009 | 64 | 2009 | $306,000 |
| Kathi Seifert (71) Independent Director since 1995 | 71 | 1995 | $302,667 |
| Marschall Runge (65) Independent Director since 2013 | 65 | 2013 | $294,000 |
| Carolyn Bertozzi (53) Independent Director since 2017 | 53 | 2017 | $294,000 |
| Alfonso Zulueta (57) Senior Vice President and President - Lilly International since 2017 | 57 | 2017 | |
| Ilya Yuffa | 2020 | ||
| Anne White (51) Senior Vice President and President - Lilly Oncology since 2018 | 51 | 2018 | |
| Leigh Pusey (57) Senior Vice President - Corporate Affairs and Communications since 2017 | 57 | 2017 | |
| Myles O'Neill (61) Senior Vice President and President - Manufacturing Operations since 2018 | 61 | 2018 | |
| Johna Norton (53) Senior Vice President - Global Quality since 2017 | 53 | 2017 | |
| Michael Mason (53) Senior Vice President, President, and Lilly Diabetes since 2020 | 53 | 2020 | |
| Patrik Jonsson (53) Senior Vice President, President of Lilly USA, and Chief Customer Officer since 2020 | 53 | 2020 | |
| Stephen Fry (54) Senior Vice President - Human Resources and Diversity since 2011 | 54 | 2011 | |
| Anat Hakim (50) Senior Vice President and General Counsel since 2020 | 50 | 2020 | |
| Melissa Barnes (52) Senior Vice President - Enterprise Risk Management, Chief Ethics, and Compliance Officer since 2013 | 52 | 2013 | |
| Aarti Shah (56) Senior Vice President - Chief Information and Digital Officer since 2018 | 56 | 2018 | |
| Leigh Ann Pusey (58) Sr. VP of Corp. Affairs and Communications | 58 | ||
| Alonzo Weems | |||
| Diogo Rau | |||
| Kevin Hern | |||
| Martin Bott MIBS (58) VP of Fin. and Special Projects | 58 | ||
| Donald A. Zakrowski | |||
| Jacob S. Van Naarden (35) Chief Operating Officer of Loxo Oncology | 35 | ||
| Anat Ashkenazi (48) Sr. VP and CFO | 48 |
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War.
- Health Care > Pharmaceuticals
- Lilly(Eli) & Co, Lilly Corporate Center, Indianapolis 46285, United States
- 317 276 2000
- Investor relations
Dividends
| Ex-dividend date | N/A | Frequency | Quarterly | Annual dividend | +15.31% |
|---|---|---|---|---|---|
| Next dividend | N/A | Dividend yield | 0.55% | Growth period | 51 years |
| Last dividend date | Yield 3 years | 0.80% | Growth 3 years | +15.15% | |
| Last dividend | Yield 5 years | 1.08% | Growth 5 years | +14.96% |
Quarterly EPS estimates
Profit margin
Debt to assets
Cash flow
Balance sheet
XSLX
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Current assets | |||||
| Cash | $2,460.2 | $2,818.6 | |||
| Short term investments | $126.1 | $109.1 | |||
| Net receivables | $10,013.5 | $11,336.2 | |||
| Inventory | $6,101.8 | $5,772.8 | |||
| Total current assets | $25,188.8 | $25,727 | |||
| Long term investments | $3,086.9 | $3,052.2 | |||
| Property, plant & equipment | $13,624 | $12,913.6 | |||
| Goodwill & intangible assets | $11,701.8 | $11,846.3 | |||
| Total noncurrent assets | $38,754.7 | $38,279.3 | |||
| Total investments | $3,213 | $3,161.3 | |||
| Total assets | $63,943.5 | $64,006.3 | |||
| Current liabilities | |||||
| Accounts payable | $2,473.7 | $2,598.8 | |||
| Deferred revenue | |||||
| Short long term debt | $1,651.5 | $6,904.5 | |||
| Total current liabilities | $18,598.1 | $27,293.2 | |||
| Long term debt | $24,559.9 | $18,320.8 | |||
| Total noncurrent liabilities | $32,448 | $25,849.4 | |||
| Total debt | $26,211.4 | $25,225.3 | |||
| Total liabilities | $51,046.1 | $53,142.6 | |||
| Stockholders' equity | |||||
| Retained earnings | $12,553.9 | $10,312.3 | |||
| Other stockholder equity | -$4,299.5 | -$4,327 | |||
| Total stockholder equity | $12,812.2 | $10,771.9 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2,818.6 | $2,067 | ||
| Short term investments | $109.1 | $144.8 | ||
| Net receivables | $11,336.2 | $8,558.9 | ||
| Inventory | $5,772.8 | $4,309.7 | ||
| Total current assets | $25,727 | $18,034.5 | ||
| Long term investments | $3,052.2 | $2,901.8 | ||
| Property, plant & equipment | $12,913.6 | $10,144 | ||
| Goodwill & intangible assets | $11,846.3 | $11,279.6 | ||
| Total noncurrent assets | $38,279.3 | $31,455.3 | ||
| Total investments | $3,161.3 | $3,046.6 | ||
| Total assets | $64,006.3 | $49,489.8 | ||
| Current liabilities | ||||
| Accounts payable | $2,598.8 | $1,930.6 | ||
| Deferred revenue | ||||
| Short long term debt | $6,904.5 | $1,501.1 | ||
| Total current liabilities | $27,293.2 | $17,138.2 | ||
| Long term debt | $18,320.8 | $14,737.5 | ||
| Total noncurrent liabilities | $25,849.4 | $21,576.2 | ||
| Total debt | $25,225.3 | $16,238.6 | ||
| Total liabilities | $53,142.6 | $38,714.4 | ||
| Stockholders' equity | ||||
| Retained earnings | $10,312.3 | $10,042.6 | ||
| Other stockholder equity | -$4,327 | -$3,844.6 | ||
| Total stockholder equity | $10,771.9 | $10,649.8 | ||
Income statement
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Revenue | |||||
| Total revenue | $8,768 | $9,353.4 | |||
| Cost of revenue | $1,673.5 | $1,788 | |||
| Gross profit | $7,094.5 | $7,565.4 | |||
| Operating activities | |||||
| Research & development | $2,522.8 | $2,562.7 | |||
| Selling, general & administrative | $1,952.2 | $1,924.6 | |||
| Total operating expenses | $4,558.4 | $5,056.6 | |||
| Operating income | $2,536.1 | $2,508.8 | |||
| Income from continuing operations | |||||
| EBIT | $2,536.1 | $2,508.8 | |||
| Income tax expense | $293.2 | $319.1 | |||
| Interest expense | |||||
| Net income | |||||
| Net income | $2,242.9 | $2,189.7 | |||
| Income (for common shares) | $2,242.9 | $2,189.7 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $34,124.1 | $28,541.4 | ||
| Cost of revenue | $7,082.2 | $6,629.8 | ||
| Gross profit | $27,041.9 | $21,911.6 | ||
| Operating activities | ||||
| Research & development | $9,313.4 | $7,190.8 | ||
| Selling, general & administrative | $7,403.1 | $6,440.4 | ||
| Total operating expenses | $20,487.3 | $15,105.2 | ||
| Operating income | $6,554.6 | $6,806.4 | ||
| Income from continuing operations | ||||
| EBIT | $6,554.6 | $6,806.4 | ||
| Income tax expense | $1,314.2 | $561.6 | ||
| Interest expense | ||||
| Net income | ||||
| Net income | $5,240.4 | $6,244.8 | ||
| Income (for common shares) | $5,240.4 | $6,244.8 | ||
Cash flows
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Net income | $2,242.9 | $2,189.7 | |||
| Operating activities | |||||
| Depreciation | $400.6 | $387.7 | |||
| Business acquisitions & disposals | -$1,044.3 | ||||
| Stock-based compensation | $159.4 | $120.2 | |||
| Total cash flows from operations | $1,166 | -$311.9 | |||
| Investing activities | |||||
| Capital expenditures | -$986.3 | -$1,070.6 | |||
| Investments | -$29.6 | -$206.1 | |||
| Total cash flows from investing | -$1,177.6 | -$2,924.3 | |||
| Financing activities | |||||
| Dividends paid | -$1,169.2 | -$1,018.1 | |||
| Sale and purchase of stock | |||||
| Net borrowings | $1,247.7 | $4,594.4 | |||
| Total cash flows from financing | -$311.3 | $3,544.7 | |||
| Effect of exchange rate | -$35.5 | $129.3 | |||
| Change in cash and equivalents | -$358.4 | $437.8 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Net income | $5,240.4 | $6,244.8 | ||
| Operating activities | ||||
| Depreciation | $1,527.3 | $1,522.5 | ||
| Business acquisitions & disposals | -$1,044.3 | -$327.2 | ||
| Stock-based compensation | $628.5 | $371.1 | ||
| Total cash flows from operations | $4,240.1 | $7,084.4 | ||
| Investing activities | ||||
| Capital expenditures | -$3,447.6 | -$1,854.3 | ||
| Investments | -$128.7 | -$244 | ||
| Total cash flows from investing | -$7,152.7 | -$3,261.6 | ||
| Financing activities | ||||
| Dividends paid | -$4,069.3 | -$3,535.8 | ||
| Sale and purchase of stock | -$750 | -$1,500 | ||
| Net borrowings | $8,649.9 | -$62 | ||
| Total cash flows from financing | $3,495.6 | -$5,406.7 | ||
| Effect of exchange rate | $168.6 | -$167.6 | ||
| Change in cash and equivalents | $751.6 | -$1,751.5 | ||
Recent institutional transactions
| Quarter | Shareholder | Change |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|---|
| 2020 Q2 | Frontier Investment Mgmt Co |
+31.41%
|
2,138 | $351 |
| 2019 Q4 | Cleararc Capital Inc |
-32.14%
|
7,882 | $1,036 |
| 2019 Q4 | Torch Wealth Management |
+0.30%
|
13,333 | $1,752 |
| 2019 Q3 | Foresters Investment Management |
-36.14%
|
138,800 | $15,522 |
| 2019 Q3 | Madison Investment Holdings Inc |
-58.83%
|
49,016 | $5,481 |
| 2019 Q3 | Sterling Capital Management |
+0.26%
|
52,333 | $5,852 |
| 2019 Q1 | Tiaa Cref Investment Management |
Opened
|
4,536,891 | $588,707 |
| 2019 Q1 | Reliance Trust Co Of Delaware |
Opened
|
16,811 | $2,181 |
| 2017 Q2 | Standard Life Investments Ltd |
+3.26%
|
2,161,631 | $177,892 |
| 2017 Q1 | Janus Capital Management |
Opened
|
8,723,692 | $733,731 |
Institutional shareholders
| Shareholder | Stake |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|
| Janus Capital Management | 0.92% | 8,723,692 | |
| Tiaa Cref Investment Management | 0.48% | 4,536,891 | |
| Standard Life Investments Ltd | 0.23% | 2,161,631 | |
| Foresters Investment Management | 0.01% | 138,800 | |
| Terry E. Patton, Esq | 0.01% | 84,166 | |
| Sterling Capital Management | 0.01% | 52,333 | |
| Madison Investment Holdings Inc | 0.01% | 49,016 | |
| Reliance Trust Co Of Delaware | 0.00% | 16,811 | |
| Torch Wealth Management | 0.00% | 13,333 | |
| Susquehanna Trust & Investment Co | 0.00% | 12,042 |
Sign up